MetaCap

UroGen Pharma Ltd. (URGN)

NASDAQ: URGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD

27.65-4.08 (-12.86%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

URGN stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.31
52-week range
16.50 – 50.81
Day range
27.58 – 31.90
Volume / Avg
2.40M / 1.11M
Beta
—

52-week range

$16.50$50.81

URGN stock today

Shares of UroGen Pharma (URGN) finished lower on Nov 20 at $27.65, a drop of 12.86% or $4.08 per share, versus the S&P 500's 3.70% decline. Volume was 2.2x the average at 2.40M shares, a sign of unusually heavy trading. At this level, URGN sits in the middle of its 52-week range of $16.50 to $50.81: 45.6% below the high, set on Aug 19, 2026 and 67.6% above the low.

URGN is up 18.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 6.9%. UroGen Pharma has posted a net loss over the last twelve months (EPS of -$1.31), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About UroGen Pharma

Company profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Ms. Elizabeth A. Barrett
Headquarters
Princeton, NJ
Employees
300
IPO year
2017
Website
urogen.com

Financial highlights

Full financials

In fiscal 2025, UroGen Pharma generated $109.8 million in revenue, up 21.4% from fiscal 2024, its 6th consecutive year of revenue growth. UroGen Pharma reported a net loss of $153.5 million, compared with a loss of $126.9 million a year earlier. Gross margin was 88.7% (down from 90.2%) and operating margin -113.7%.

UroGen Pharma annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$109.79M$90.40M$82.71M$64.36M$48.04M
Growth+21.45%+9.29%+28.52%+33.96%+307.17%
Net income$-153.49M$-126.87M$-102.24M$-109.78M$-110.82M
EPS (diluted)————$-4.96

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$60.71+119.57%

  • Strong buy 1
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $54.00High $75.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.03 vs $0.05
Surprise
-160.00%

URGN news

All URGN news

UroGen Pharma peers

Health Care sector
URGN peer companies
CompanyPrice% ChgMarket capCompare
QUREuniQure N.V.19.35-4.35%$1.36Bvs URGN
PAHCPhibro Animal Health Corporation Class A33.29-2.32%$1.35Bvs URGN
NBTXNanobiotix S.A. ADR26.50-2.98%$1.35Bvs URGN
NUVBNuvation Bio Inc. Class A3.80-0.26%$1.34Bvs URGN
RAPPRapport Therapeutics Inc.23.16-1.82%$1.37Bvs URGN
ANABAnaptysBio Inc.46.63-1.62%$1.39Bvs URGN
TYRATyra Biosciences Inc.20.12+1.98%$1.39Bvs URGN
NRIXNurix Therapeutics Inc.12.85-5.55%$1.40Bvs URGN

Indexes, lists and sector

UroGen Pharma stock FAQ

What is UroGen Pharma's stock price today?

URGN last traded at $27.65 as of Nov 20, 4:00 PM EST, down 12.86% on the day. Prices are delayed at least 15 minutes.

Who is UroGen Pharma's CEO?

Ms. Elizabeth A. Barrett is the chief executive officer of UroGen Pharma Ltd., which has about 300 employees.

What is the URGN 52-week high?

The 52-week high for URGN is $50.81 and the 52-week low is $16.50. The stock is currently 45.6% below its high.

Compare URGN